Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
6 authors at 2 institutions in 1 country.
Cai BowenDepartments of Medicine, Genetics & Development, Urology and Systems Biology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York.
Maho ShibataDepartments of Medicine, Genetics & Development, Urology and Systems Biology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York.ORCID 0000-0002-7056-3939
Hailan ZhangDivision of Hematology/Oncology, University of Arizona Medical Center, Tucson, Arizona.
Sarah K BergrenDepartments of Medicine, Genetics & Development, Urology and Systems Biology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York.
Michael M ShenDepartments of Medicine, Genetics & Development, Urology and Systems Biology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York.ORCID 0000-0002-4042-1657
Edward P GelmannDivision of Hematology/Oncology, University of Arizona Medical Center, Tucson, Arizona. gelmanne@arizona.edu.ORCID 0000-0003-1482-3334
Columbia University Irving Medical Center · USBanner - University Medical Center Tucson · US
Funding
Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Parisa Tehranifar · 1985 to 2026
$115.3M
VITAMIN AP30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Dan Theodorescu · 1985 to 2026
$110.2M
Roles for Nkx3.1 in Prostate Cancer InitiationP01CA154293 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CORDON-CARDO, CARLOS · 2011 to 2015
$6.5M
Analysis of epithelial heterogeneity in prostate development and cancerR01CA238005 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SHEN, MICHAEL M. · 2019 to 2023
$2.1M
Investigation of luminal stem cells and castration resistance in prostate cancerK99CA194287 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SHIBATA, MAHO · 2015 to 2016
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
CRISPR/Cas9-Mediated Point Mutation in · full record | OpenQuestion